(MedPage Today) — The FDA expanded the indication for setmelanotide (Imcivree) to include children as young as 2 years with syndromic or monogenic obesity due to Bardet-Biedl syndrome or genetically confirmed pro-opiomelanocortin, said maker Rhythm…